Zentek Granted Second Patent from the Canadian Intellectual Patent Office

Zentek Ltd. has secured a second patent from the Canadian Intellectual Property Office for its Graphene Oxide-Cationic Silver (GO-Ag+) Nanocomposites. The patent, encompassing 64 claims, positions GO-Ag+ as a broad-spectrum antimicrobial agent effective against bacteria, fungi, and viruses. This follows an additional application with the United States Patent and Trademark Office. The IP covers liquid, powder, and ointments utilizing GO-Ag+.

Zentek collaborates with the University of Guelph on ongoing research. Previous findings showed GO-Ag+ has higher cytotoxicity on bacteria than human epithelial cells. Current studies aim at GO-Ag+'s efficacy in combating biofilms, a significant issue in wound care and medical devices, supporting future product developments for medical and veterinary markets.

Greg Fenton, CEO, regards this patent as essential for enhancing the IP commercialization strategy. The securement of this patent enables potential therapeutic applications in human and veterinary medicine, steering Zentek to explore ways to maximize shareholder value from this development.